These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 1685663

  • 1. Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism.
    Turgeon J, Evans WE, Relling MV, Wilkinson GR, Roden DM.
    Br J Clin Pharmacol; 1991 Sep; 32(3):283-8. PubMed ID: 1685663
    [Abstract] [Full Text] [Related]

  • 2. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE, Relling MV.
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
    Romkes-Sparks M, Mnuskin A, Chern HD, Persad R, Fleming C, Sibley GN, Smith P, Wilkinson GR, Branch RA.
    Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
    [Abstract] [Full Text] [Related]

  • 5. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.
    Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Sorsa M, Vainio H.
    Pharmacogenetics; 1992 Dec; 2(6):259-63. PubMed ID: 1306126
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans.
    Funck-Brentano C, Thomas G, Jacqz-Aigrain E, Poirier JM, Simon T, Béréziat G, Jaillon P.
    J Pharmacol Exp Ther; 1992 Nov; 263(2):780-6. PubMed ID: 1432700
    [Abstract] [Full Text] [Related]

  • 9. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
    Broly F, Meyer UA.
    Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
    [Abstract] [Full Text] [Related]

  • 10. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
    Sugimura H, Caporaso NE, Shaw GL, Modali RV, Gonzalez FJ, Hoover RN, Resau JH, Trump BF, Weston A, Harris CC.
    Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046
    [Abstract] [Full Text] [Related]

  • 11. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.
    Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR.
    Pharmacogenetics; 1991 Oct; 1(1):33-41. PubMed ID: 1688241
    [Abstract] [Full Text] [Related]

  • 12. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
    Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F.
    Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
    [Abstract] [Full Text] [Related]

  • 13. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.
    Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA.
    J Biol Chem; 1990 Oct 05; 265(28):17209-14. PubMed ID: 2211621
    [Abstract] [Full Text] [Related]

  • 14. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
    Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M.
    J Pharmacol Exp Ther; 1996 Jul 05; 278(1):441-6. PubMed ID: 8764380
    [Abstract] [Full Text] [Related]

  • 15. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.
    Skoda RC, Gonzalez FJ, Demierre A, Meyer UA.
    Proc Natl Acad Sci U S A; 1988 Jul 05; 85(14):5240-3. PubMed ID: 2899325
    [Abstract] [Full Text] [Related]

  • 16. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
    Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Pelkonen O, Vainio H.
    Pharmacogenetics; 1993 Feb 05; 3(1):19-27. PubMed ID: 8097947
    [Abstract] [Full Text] [Related]

  • 17. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
    Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M.
    Proc Natl Acad Sci U S A; 1993 Dec 15; 90(24):11825-9. PubMed ID: 7903454
    [Abstract] [Full Text] [Related]

  • 18. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6.
    Wang SL, Huang JD, Lai MD, Liu BH, Lai ML.
    Clin Pharmacol Ther; 1993 Apr 15; 53(4):410-8. PubMed ID: 8097442
    [Abstract] [Full Text] [Related]

  • 19. Oxidative metabolism of encainide: polymorphism, pharmacokinetics and clinical considerations.
    McAllister CB, Wolfenden HT, Aslanian WS, Woosley RL, Wilkinson GR.
    Xenobiotica; 1986 May 15; 16(5):483-90. PubMed ID: 3090789
    [Abstract] [Full Text] [Related]

  • 20. Debrisoquine hydroxylase and Parkinson's disease.
    Kondo I, Kanazawa I.
    Adv Neurol; 1993 May 15; 60():338-42. PubMed ID: 8420147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.